Renal denervation reverses hepatic insulin resistance induced by high-fat diet

Diabetes

Volumn 65, Issue 11, 2016, Pages 3453-3463

  Iyer, Malini S ^a   Bergman, Richard N ^a   Korman, Jeremy E ^a   Woolcott, Orison O ^a   Kabir, Morvarid ^a   Victor, Ronald G ^a   Clegg, Deborah J ^a   Kolka, Cathryn ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ANTIDIABETIC AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CREATININE; EPINEPHRINE; G PROTEIN COUPLED RECEPTOR; GLUCOSE 6 PHOSPHATASE; INSULIN; KETONE; LIVER X RECEPTOR ALPHA; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR FKHR; LIVER X RECEPTOR; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DENERVATION; KIDNEY NERVE; LIPID DIET; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SHAM PROCEDURE; SURGICAL APPROACH; UPREGULATION; ADRENERGIC SYSTEM; ADVERSE EFFECTS; ANIMAL; BLOOD; DOG; GENETICS; GLUCOSE CLAMP TECHNIQUE; INNERVATION; KIDNEY; LIVER; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CATECHOLAMINES; DIET, HIGH-FAT; DOGS; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; HYPOGLYCEMIA; INSULIN; INSULIN RESISTANCE; KIDNEY; LIVER; LIVER X RECEPTORS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RENIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 84994252957     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0698     Document Type: Article

References (50)

1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281
2. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946
3. Dibona GF. The functions of the renal nerves. In: Reviews of Physiology, Biochemistry and Pharmacology. Vol. 94. Adrian RH, zur Hausen H, Helmreich E, et al., Eds. New York, Springer-Verlag, 1982, p. 75-181
4. Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst 1981;3:237-251
5. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116:991-1006
6. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918
7. Bhatt DL, Kandzari DE, O'Neill WW, et al.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-1401
8. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011;29:991-996
9. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011;58:559-565
10. Denker MG, Cohen DL, Townsend RR. Catheter-based renal artery denervation for resistant hypertension: promise unfulfilled or unsettled? Curr Atheroscler Rep 2015;17:56
11. Pekarskiy S, Baev A, Mordovin V, et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not true limitations of the technology. J Hypertens 2015;33(Suppl. 1):e108
12. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of dietinduced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 2007;292:E1590-E1598
13. Ader M, Stefanovski D, Richey JM, et al. Failure of homeostatic model assessment of insulin resistance to detect marked diet-induced insulin resistance in dogs. Diabetes 2014;63:1914-1919
14. Ader M, Stefanovski D, Kim SP, et al. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. Obesity (Silver Spring) 2014;22:1238-1245
15. Ganong WF. Sympathetic effects on renin secretion: mechanism and physiological role [Internet], 1972. New York, Springer. Available from http://link.springer .com/chapter/10.1007/978-1-4684-0940-6-2. Accessed 2 October 2015
16. Otsuka K, Assaykeen TA, Goldfien A, Ganong WF. Effect of hypoglycemia on plasma renin activity in dogs. Endocrinology 1970;87:1306-1317
17. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 2003;100:5419-5424
18. Cannon MV, Silljé HHW, Sijbesma JWA, et al. LXRa improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesityinduced type 2 diabetes. Diabetologia 2016;59:634-643
19. Palmer BF, Clegg DJ. An emerging role of natriuretic peptides: igniting the fat furnace to fuel and warm the heart. Mayo Clin Proc 2015;90:1666-1678
20. Exton JH. Mechanisms involved in alpha-adrenergic phenomena: role of calcium ions in actions of catecholamines in liver and other tissues. Am J Physiol 1980;238:E3-E12
21. Zhong H, Minneman KP. Alpha1-adrenoceptor subtypes. Eur J Pharmacol 1999;375:261-276
22. Berecek KH, Brody MJ. Evidence for a neurotransmitter role for epinephrine derived from the adrenal medulla. Am J Physiol 1982;242:H593-H601
23. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97
24. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806
25. Merkulov VM, Merkulova TI. Structural variants of glucocorticoid receptor binding sites and different versions of positive glucocorticoid responsive elements: analysis of GR-TRRD database. J Steroid Biochem Mol Biol 2009;115:1-8
26. Exton JH, Mallette LE, Jefferson LS, et al. The hormonal control of hepatic gluconeogenesis. Recent Prog Horm Res 1970;26:411-461
27. Han C, Bowen WC, Michalopoulos GK, Wu T. Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. J Cell Physiol 2008;216:486-497
28. Diaz-Cruz A, Vilchis-Landeros MM, Guinzberg R, Villalobos-Molina R, Piña E. NOX2 activated by a1-adrenoceptors modulates hepatic metabolic routes stimulated by b-adrenoceptors. Free Radic Res 2011;45:1366-1378
29. Rafiq K, Fujisawa Y, Sherajee SJ, et al. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 2015;58:2885-2898
30. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 1999;48:1093-1100
31. Ahrén B, Lundquist I. Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse. Horm Metab Res 1987;19:600-603
32. Miroslawska AK, Gjessing PF, Solbu MD, Fuskevåg OM, Jenssen TG, Steigen TK. Renal denervation for resistant hypertension fails to improve insulin resistance as assessed by hyperinsulinemic-euglycemic step clamp. Diabetes 2016;65:2164-2168
33. Bergman RN. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 1997;52:359-385; discussion 385-387
34. Ciriello J, Calaresu FR. Hypothalamic projections of renal afferent nerves in the cat. Can J Physiol Pharmacol 1980;58:574-576
35. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8:1376-1382
36. Rojas JM, Schwartz MW. Control of hepatic glucose metabolism by islet and brain. Diabetes Obes Metab 2014;16(Suppl. 1):33-40
37. Pocai A, Lam TKT, Gutierrez-Juarez R, et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005;434:1026-1031
38. Hartmann H, Beckh K, Jungermann K. Direct control of glycogen metabolism in the perfused rat liver by the sympathetic innervation. Eur J Biochem 1982;123:521-526
39. Shimazu T. Innervation of the liver and glucoregulation: roles of the hypothalamus and autonomic nerves. Nutrition 1996;12:65-66
40. Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol 1990;258:E1020-E1032
41. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000;43:946-952
42. Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 2000;279:E630-E637
43. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999;277:R332-R336
44. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991;14(Suppl. 4):39-47
45. Seefeldt T, Ørskov L, Mengel A, et al. Lack of effects of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes. Diabet Med 1990;7:700-704
46. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a metaanalysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-826
47. Cherrington AD, Fuchs H, Stevenson RW, Williams PE, Alberti KG, Steiner KE. Effect of epinephrine on glycogenolysis and gluconeogenesis in conscious overnight-fasted dogs. Am J Physiol 1984;247:E137-E144
48. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999;17:719-734
49. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf) 2012;77:791-801
50. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321